# Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

> **NCT01079481** · PHASE1 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 21 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** taxol plus everolimus

## Key facts

- **NCT ID:** NCT01079481
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-05
- **Final completion:** 2013-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2013-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01079481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01079481, "Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01079481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*